MCID: ADR004
MIFTS: 48

Adrenal Cortical Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Adrenal Cortical Adenocarcinoma

MalaCards integrated aliases for Adrenal Cortical Adenocarcinoma:

Name: Adrenal Cortical Adenocarcinoma 12 15
Adrenal Cortex Adenocarcinoma 12
Adrenocortical Carcinoma 73

Classifications:



External Ids:

Disease Ontology 12 DOID:3959
UMLS 73 C0206686

Summaries for Adrenal Cortical Adenocarcinoma

Disease Ontology : 12 An adrenocortical carcinoma that originates in the cortex of the adrenal gland and derives from epithelial cells of glandular origin.

MalaCards based summary : Adrenal Cortical Adenocarcinoma, also known as adrenal cortex adenocarcinoma, is related to legius syndrome and breast adenocarcinoma, and has symptoms including fever and flank pain. An important gene associated with Adrenal Cortical Adenocarcinoma is SPRY2 (Sprouty RTK Signaling Antagonist 2), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Racepinephrine and Epinephrine have been mentioned in the context of this disorder. Affiliated tissues include cortex, adrenal gland and adrenal cortex, and related phenotypes are Decreased cell migration and Decreased viability with paclitaxel

Related Diseases for Adrenal Cortical Adenocarcinoma

Diseases related to Adrenal Cortical Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 legius syndrome 10.0 SPRY1 SPRY2
2 breast adenocarcinoma 9.7 EGF PTEN SH3KBP1
3 endometrial cancer 9.6 EGF MAPK3 MME PTEN

Symptoms & Phenotypes for Adrenal Cortical Adenocarcinoma

UMLS symptoms related to Adrenal Cortical Adenocarcinoma:


fever, flank pain

GenomeRNAi Phenotypes related to Adrenal Cortical Adenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.26 CBL MAPK3 RPS6KA1 SPRY1
2 Decreased viability with paclitaxel GR00179-A-1 9.23 MAPK3 SP1
3 Decreased viability with paclitaxel GR00179-A-3 9.23 MAPK3 SP1

MGI Mouse Phenotypes related to Adrenal Cortical Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.8 BAD CBL EGF MAPK3 PTEN SPRY1
2 integument MP:0010771 9.7 CBL EGF MAPK3 MME PTEN SH3KBP1
3 liver/biliary system MP:0005370 9.43 CBL DECR1 MAPK3 MME PTEN SP1
4 neoplasm MP:0002006 9.02 BAD MAPK3 PTEN SPRY1 SPRY2

Drugs & Therapeutics for Adrenal Cortical Adenocarcinoma

Drugs for Adrenal Cortical Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 162)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Racepinephrine Approved Phase 3,Phase 2,Phase 1,Not Applicable 329-65-7 838
2
Epinephrine Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 51-43-4 5816
3
Mecasermin Approved, Investigational Phase 3 68562-41-4
4
Mitotane Approved Phase 3,Phase 2 53-19-0 4211
5
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
6
Streptozocin Approved, Investigational Phase 3 18883-66-4 29327
7
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
8
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
9
Lenograstim Approved, Investigational Phase 3 135968-09-1
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
11
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2 50-23-7 5754
12
Hydrocortisone acetate Approved, Vet_approved Phase 3,Phase 2 50-03-3
13
Mifepristone Approved, Investigational Phase 3 84371-65-3 55245
14
Etomidate Approved Phase 3,Phase 1,Phase 2 33125-97-2 667484 36339
15
Isotretinoin Approved Phase 3 4759-48-2 5538 5282379
16
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 5538 444795
17
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
18 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
19 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
20 Cola Phase 3,Phase 2,Phase 1,Early Phase 1
21 Liver Extracts Phase 3,Phase 2,Phase 1,Early Phase 1
22 Peripheral Nervous System Agents Phase 3,Phase 2,Not Applicable
23 Epinephryl borate Phase 3,Phase 2,Phase 1,Not Applicable
24 Antimitotic Agents Phase 3,Phase 2,Phase 1
25 Vasoconstrictor Agents Phase 3,Phase 2,Not Applicable
26 Adrenergic beta-Agonists Phase 3,Phase 2,Not Applicable
27 Anti-Asthmatic Agents Phase 3,Phase 2,Not Applicable
28 Mydriatics Phase 3,Phase 2,Not Applicable
29 Adrenergic alpha-Agonists Phase 3,Phase 2,Not Applicable
30 Autonomic Agents Phase 3,Phase 2,Not Applicable
31 Sympathomimetics Phase 3,Phase 2,Not Applicable
32 Adrenergic Agonists Phase 3,Phase 2,Not Applicable
33 Respiratory System Agents Phase 3,Phase 2,Not Applicable
34 Bronchodilator Agents Phase 3,Phase 2,Not Applicable
35 Adrenergic Agents Phase 3,Phase 2,Not Applicable
36 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
37 Insulin, Globin Zinc Phase 3,Phase 2
38 insulin Phase 3,Phase 2
39 Mitogens Phase 3,Phase 2
40 Antineoplastic Agents, Hormonal Phase 3,Phase 2
41 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
42 Etoposide phosphate Phase 3,Phase 2
43 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
44 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
45 Immunologic Factors Phase 3,Phase 2,Phase 1
46 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
47 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
48 Adjuvants, Anesthesia Phase 3
49 Anesthetics, Intravenous Phase 3,Phase 1,Phase 2
50 Analgesics, Opioid Phase 3

Interventional clinical trials:

(show top 50) (show all 76)
# Name Status NCT ID Phase Drugs
1 A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Completed NCT00924989 Phase 3 OSI-906
2 Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) Completed NCT00094497 Phase 3 Etoposide;Doxorubicin;Cisplatin;Streptozotocin;Mitotane
3 Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor Completed NCT00304070 Phase 3 doxorubicin hydrochloride;cisplatin;mitotane;etoposide
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00936741 Phase 3 mifepristone
6 A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00569582 Phase 3 mifepristone
7 Adjuvant Chemotherapy vs. Observation/Mitotane After Primary Surgical Resection of Localized Adrenocortical CarcInoma Recruiting NCT03723941 Phase 3 Cisplatin plus Etoposide
8 Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence (ADIUVO-2) Recruiting NCT03583710 Phase 3 Cisplatin;Etoposide;Mitotane
9 Efficacy of Adjuvant Mitotane Treatment (ADIUVO) Recruiting NCT00777244 Phase 3 MITOTANE
10 Combined FDG-PET and 123I-Iodometomidate Imaging for Adrenal Neoplasia Recruiting NCT02010957 Phase 3
11 European Low and Intermediate Risk Neuroblastoma Protocol Recruiting NCT01728155 Phase 3 chemotherapy
12 Sunitinib in Refractory Adrenocortical Carcinoma Unknown status NCT00453895 Phase 2 Sunitinib
13 Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients Unknown status NCT00786110 Phase 2 Sorafenib;Paclitaxel
14 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
15 Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma Completed NCT01514526 Phase 2 Dovitinib
16 Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC) Completed NCT00215202 Phase 2 Iressa (ZD1839)
17 Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma Completed NCT00324012 Phase 2 cisplatin, taxotere
18 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer Completed NCT01255137 Phase 2 Axitinib
19 Surgery and Heated Chemotherapy for Adrenocortical Carcinoma Completed NCT01833832 Phase 2 Cisplatin;sodium thiosulfate
20 Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery Completed NCT00848016 Phase 2 R-(-)-gossypol acetic acid
21 A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection Completed NCT00001339 Phase 2 doxorubicin, vincristine, and etoposide with mitotane
22 Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer Completed NCT00071058 Phase 2 XR9576 (Tariquidar)
23 A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients Completed NCT01262235 Phase 1, Phase 2 TKM-080301
24 Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy Completed NCT00454103 Phase 1, Phase 2 123I-Iodometomidate
25 A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent Completed NCT00264433 Phase 2 ADH -1 (Exherin™)
26 Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome Completed NCT02468193 Phase 2 Osilodrostat
27 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
28 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
29 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
30 Study to Evaluate CORT125134 in Patients With Cushing's Syndrome Completed NCT02804750 Phase 2 CORT125134
31 Cabozantinib in Unresectable/Metastatic Adrenocortical Carcinoma Recruiting NCT03370718 Phase 2 Cabozantinib
32 Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy Lines Recruiting NCT03257891 Phase 2 Cabazitaxel
33 Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma Recruiting NCT03127774 Phase 2 Cisplatin;Sodium thiosulfate
34 Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Recruiting NCT02673333 Phase 2 Pembrolizumab
35 Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Recruiting NCT03333616 Phase 2 Ipilimumab;Nivolumab
36 Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Recruiting NCT02867592 Phase 2 Cabozantinib S-malate
37 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
38 Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic Recruiting NCT02721732 Phase 2
39 Extension Study to Evaluate the Safety and Clinical Benefit of Long-Term Use of Relacorilant in Patients With Cushing Syndrome Recruiting NCT03604198 Phase 2 relacorilant
40 Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma Active, not recruiting NCT03145285 Phase 2 Abiraterone Acetate
41 Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer Active, not recruiting NCT02720484 Phase 2 Nivolumab
42 Cabozantinib in Advanced Adrenocortical Carcinoma Not yet recruiting NCT03612232 Phase 2 Cabozantinib-s-malate
43 S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery Terminated NCT00002921 Phase 2 suramin;therapeutic hydrocortisone
44 IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery Terminated NCT00778817 Phase 2 mitotane
45 Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer Terminated NCT00003453 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
46 Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma Withdrawn NCT00469469 Phase 2 Bevacizumab
47 Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma Completed NCT01898715 Phase 1 ATR-101
48 Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors Completed NCT00003038 Phase 1 doxorubicin hydrochloride;suramin
49 A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome Completed NCT01981525 Phase 1 Metformin
50 Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Completed NCT01048892 Phase 1 cyclophosphamide

Search NIH Clinical Center for Adrenal Cortical Adenocarcinoma

Genetic Tests for Adrenal Cortical Adenocarcinoma

Anatomical Context for Adrenal Cortical Adenocarcinoma

MalaCards organs/tissues related to Adrenal Cortical Adenocarcinoma:

41
Cortex, Adrenal Gland, Adrenal Cortex, Liver, Testes, Bone, Lymph Node

Publications for Adrenal Cortical Adenocarcinoma

Articles related to Adrenal Cortical Adenocarcinoma:

(show top 50) (show all 1006)
# Title Authors Year
1
Co-culture of H295R Adrenocortical Carcinoma and BeWo Choriocarcinoma Cells to Study Feto-placental Interactions: Focus on Estrogen Biosynthesis. ( 29197012 )
2018
2
Adrenocortical carcinoma characterized by gynecomastia: A case report. ( 29403152 )
2018
3
Synchronous adrenocortical carcinoma and ovarian malignant mixed germ cell tumor: A case report and literature review. ( 29768344 )
2018
4
Adrenocortical Carcinoma Presenting as Reversible Dilated Cardiomyopathy. ( 30505399 )
2018
5
High-Dose Mitotane-Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma. ( 29192018 )
2018
6
Incidentally detected adrenocortical carcinoma in familial adenomatous polyposis: an unusual presentation of a hereditary cancer syndrome. ( 30181409 )
2018
7
The coexistence of Cushing syndrome and gynecomastia as the manifestations of adrenocortical carcinoma. ( 30527206 )
2018
8
Composite Adrenocortical Carcinoma and Neuroblastoma in an Infant With a TP53 Germline Mutation: A Case Report and Literature Review. ( 29746440 )
2018
9
Identification of Five Genes as a Potential Biomarker for Predicting Progress and Prognosis in Adrenocortical Carcinoma. ( 30519354 )
2018
10
ASO Author Reflections: PTTG1 Protein Expression in Adrenocortical Carcinoma. ( 30519761 )
2018
11
A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the US Adrenocortical Carcinoma Study Group. ( 29164414 )
2018
12
Detection and monitoring of circulating tumor DNA in adrenocortical carcinoma. ( 29212777 )
2018
13
STMN1 is Overexpressed in Adrenocortical Carcinoma and Promotes a More Aggressive Phenotype In Vitro. ( 29214451 )
2018
14
Protein Expression of PTTG1 as a Diagnostic Biomarker in Adrenocortical Carcinoma. ( 29218429 )
2018
15
Images: Port site recurrence on followup imaging after adrenalectomy for adrenocortical carcinoma - first indicator of carcinomatosis. ( 29283086 )
2018
16
Laparoscopic Versus Open Adrenalectomy for Localized/Locally Advanced Primary Adrenocortical Carcinoma (ENSAT I-III) in Adults: Is Margin-Free Resection the Key Surgical Factor that Dictates Outcome? A Review of the Literature. ( 29319399 )
2018
17
The impact of patient-, disease-, and treatment-related factors on survival in patients with adrenocortical carcinoma. ( 29319480 )
2018
18
Delayed presentation of a virilising, pure testosterone-secreting adrenocortical carcinoma with coexistent composite myelolipoma and a venous thrombus extending to the heart. ( 29367375 )
2018
19
Development of new preclinical models to advance adrenocortical carcinoma research. ( 29371329 )
2018
20
Targeting the multidrug transporter Patched potentiates chemotherapy efficiency on adrenocortical carcinoma in vitro and in vivo. ( 29411361 )
2018
21
BCL9 Upregulation in Adrenocortical Carcinoma: A Novel Wnt/β-Catenin Activating Event Driving Adrenocortical Malignancy. ( 29428231 )
2018
22
Adrenocortical carcinoma: where we stand. ( 29442479 )
2018
23
Analysis of 10 Adrenocortical Carcinoma Patients in the Cohort of the Precision Medicine Platform MONDTI. ( 29444511 )
2018
24
Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma. ( 29452402 )
2018
25
BILATERAL ADRENOCORTICAL CARCINOMA: CASE REPORT AND REVIEW OF LITERATURE. ( 29461221 )
2018
26
Yttrium-90 microsphere selective internal radiation therapy for liver metastases following systemic chemotherapy and surgical resection for metastatic adrenocortical carcinoma. ( 29468134 )
2018
27
The GRP78/BiP inhibitor HA15 synergizes with mitotane action against adrenocortical carcinoma cells through convergent activation of ER stress pathways. ( 29474877 )
2018
28
MANAGEMENT OF ENDOCRINE DISEASE: Adrenocortical carcinoma: differentiating the good from the poor prognosis tumors. ( 29475877 )
2018
29
Impact of Micro- and Macroscopically Positive Surgical Margins on Survival after Resection of Adrenocortical Carcinoma. ( 29500765 )
2018
30
A case of adrenocortical carcinoma accompanying secondary acute adrenal hypofunction postoperation. ( 29506536 )
2018
31
The tyrosine kinase inhibitor nilotinib is more efficient than mitotane in decreasing cell viability in spheroids prepared from adrenocortical carcinoma cells. ( 29507530 )
2018
32
Nutlin-3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation. ( 29532999 )
2018
33
Prostate-Specific Membrane Antigen Expression in Adrenocortical Carcinoma on 68Ga-Prostate-Specific Membrane Antigen PET/CT. ( 29578871 )
2018
34
Open adrenalectomy versus laparoscopic adrenalectomy for adrenocortical carcinoma: a retrospective comparative study on short-term oncologic prognosis. ( 29606881 )
2018
35
A rare cause of dysregulated metabolic syndrome: cortisol-producing adrenocortical carcinoma. ( 29667589 )
2018
36
β-Catenin-driven adrenocortical carcinoma is characterized with immune exclusion. ( 29670378 )
2018
37
Prognostic factors in adrenocortical carcinoma: data from a large Polish series. ( 29726479 )
2018
38
CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells. ( 29734384 )
2018
39
Immunohistochemical expression of glypican-3 in adrenocortical carcinoma: A potential cause of diagnostic pitfalls. ( 29748062 )
2018
40
Adjuvant Radiation is Associated with Improved Survival for Select Patients with Non-metastatic Adrenocortical Carcinoma. ( 29748889 )
2018
41
Bone metastasis located on foot as a clinical presentation of an adrenocortical carcinoma. ( 29752041 )
2018
42
Adrenocortical Carcinoma with Hypercortisolism. ( 29754640 )
2018
43
MECHANISMS OF ENDOCRINOLOGY: Cell cycle regulation in adrenocortical carcinoma. ( 29773584 )
2018
44
Elucidating the Role of the Maternal Embryonic Leucine Zipper Kinase in Adrenocortical Carcinoma. ( 29790920 )
2018
45
Adrenocortical Carcinoma in Children: A Clinicopathological Analysis of 41 Patients at the Mayo Clinic from 1950 to 2017. ( 29804118 )
2018
46
Nicotinamide Nucleotide Transhydrogenase as a Novel Treatment Target in Adrenocortical Carcinoma. ( 29850793 )
2018
47
Role of Additional Organ Resection in Adrenocortical Carcinoma: Analysis of 167 Patients from the U.S. Adrenocortical Carcinoma Database. ( 29868977 )
2018
48
SLC12A7 alters adrenocortical carcinoma cell adhesion properties to promote an aggressive invasive behavior. ( 29884238 )
2018
49
TERT promoter hypermethylation is associated with poor prognosis in adrenocortical carcinoma. ( 29956721 )
2018
50
Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis. ( 29967789 )
2018

Variations for Adrenal Cortical Adenocarcinoma

Expression for Adrenal Cortical Adenocarcinoma

Search GEO for disease gene expression data for Adrenal Cortical Adenocarcinoma.

Pathways for Adrenal Cortical Adenocarcinoma

Pathways related to Adrenal Cortical Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 BAD CBL EGF MAPK3 PTEN RPS6KA1
2
Show member pathways
13.9 BAD CBL EGF MAPK3 MME PTEN
3
Show member pathways
13.32 BAD CBL EGF MAPK3 PTEN SH3KBP1
4
Show member pathways
13.16 BAD CBL EGF MAPK3 RPS6KA1
5
Show member pathways
13.1 BAD CBL EGF MAPK3 PTEN RPS6KA1
6
Show member pathways
12.81 BAD CBL EGF MAPK3 PTEN RPS6KA1
7
Show member pathways
12.79 BAD EGF MAPK3 PTEN
8
Show member pathways
12.76 BAD CBL EGF MAPK3 PTEN
9
Show member pathways
12.75 BAD MAPK3 PTEN RPS6KA1
10 12.73 BAD CBL EGF MAPK3 PTEN SP1
11
Show member pathways
12.68 BAD CBL MAPK3 PTEN RPS6KA1
12
Show member pathways
12.66 BAD EGF MAPK3 PTEN SP1
13
Show member pathways
12.61 BAD CBL EGF MAPK3 PTEN SH3KBP1
14
Show member pathways
12.58 BAD EGF MAPK3 SP1
15
Show member pathways
12.58 BAD CBL MAPK3 PTEN RPS6KA1 SH3KBP1
16
Show member pathways
12.56 CBL MAPK3 PTEN SP1
17
Show member pathways
12.49 BAD CBL EGF MAPK3 RPS6KA1
18
Show member pathways
12.48 BAD CBL MAPK3 PTEN
19
Show member pathways
12.42 CBL MAPK3 PTEN RPS6KA1
20
Show member pathways
12.39 BAD CBL EGF MAPK3 SP1
21
Show member pathways
12.37 BAD CBL EGF MAPK3 PTEN SP1
22
Show member pathways
12.35 BAD CBL MAPK3 RPS6KA1
23
Show member pathways
12.31 BAD CBL MAPK3 PTEN RPS6KA1
24
Show member pathways
12.3 CBL MAPK3 PTEN RPS6KA1
25
Show member pathways
12.3 BAD CBL MAPK3 PTEN RPS6KA1 SP1
26
Show member pathways
12.24 BAD CBL MAPK3 RPS6KA1 SP1
27
Show member pathways
12.23 CBL MAPK3 PTEN
28
Show member pathways
12.22 EGF MAPK3 RPS6KA1
29
Show member pathways
12.17 CBL MAPK3 SPRY2
30
Show member pathways
12.12 MAPK3 RPS6KA1 SP1
31
Show member pathways
12.09 BAD MAPK3 RPS6KA1
32
Show member pathways
12.06 CBL EGF MAPK3 PTEN
33
Show member pathways
12.06 BAD CBL MAPK3 PTEN RPS6KA1
34 12.05 BAD PTEN SP1
35 12.02 BAD MAPK3 RPS6KA1
36
Show member pathways
11.99 EGF MAPK3 PTEN
37
Show member pathways
11.98 CBL MAPK3 RPS6KA1
38 11.97 CBL EGF SH3KBP1 SPRY1 SPRY2
39
Show member pathways
11.96 BAD MAPK3 RPS6KA1
40 11.96 BAD EGF MAPK3
41 11.95 BAD MAPK3 PTEN
42
Show member pathways
11.93 BAD MAPK3 RPS6KA1
43 11.87 EGF MAPK3 PTEN
44 11.83 BAD EGF MAPK3
45 11.71 BAD MAPK3 RPS6KA1 SPRY1 SPRY2
46 11.62 EGF MAPK3 SP1
47
Show member pathways
11.52 CBL EGF MAPK3
48 11.41 BAD EGF MAPK3
49 11.41 CBL MAPK3 RPS6KA1 SPRY2
50 11.38 CBL EGF PTEN RPS6KA1 SH3KBP1 SP1

GO Terms for Adrenal Cortical Adenocarcinoma

Cellular components related to Adrenal Cortical Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.81 BAD CBL DECR1 MAPK3 PTEN RPS6KA1
2 cytoplasm GO:0005737 9.65 BAD CBL MAPK3 MME PTEN RPS6KA1
3 focal adhesion GO:0005925 8.92 CBL MAPK3 MME SH3KBP1

Biological processes related to Adrenal Cortical Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.86 CBL PTEN RPS6KA1 SPRY2
2 apoptotic process GO:0006915 9.77 BAD MAPK3 PTEN RPS6KA1 SH3KBP1
3 membrane organization GO:0061024 9.63 CBL EGF SH3KBP1
4 response to ethanol GO:0045471 9.58 BAD CBL PTEN
5 response to testosterone GO:0033574 9.57 BAD CBL
6 ERK1 and ERK2 cascade GO:0070371 9.55 EGF MAPK3
7 branching morphogenesis of an epithelial tube GO:0048754 9.54 EGF SPRY2
8 negative regulation of Ras protein signal transduction GO:0046580 9.52 SPRY1 SPRY2
9 establishment of mitotic spindle orientation GO:0000132 9.51 SPRY1 SPRY2
10 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.5 PTEN SPRY1 SPRY2
11 lung morphogenesis GO:0060425 9.49 MAPK3 SPRY2
12 negative regulation of fibroblast growth factor receptor signaling pathway GO:0040037 9.48 SPRY1 SPRY2
13 positive regulation of ubiquitin-dependent protein catabolic process GO:2000060 9.43 EGF PTEN
14 positive regulation of gene expression GO:0010628 9.35 EGF MAPK3 PTEN SP1 SPRY2
15 bud elongation involved in lung branching GO:0060449 9.26 SPRY1 SPRY2
16 negative regulation of neurotrophin TRK receptor signaling pathway GO:0051387 9.16 SPRY1 SPRY2
17 negative regulation of epidermal growth factor receptor signaling pathway GO:0042059 9.02 CBL EGF SH3KBP1 SPRY1 SPRY2

Molecular functions related to Adrenal Cortical Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.26 BAD CBL PTEN SPRY2
2 epidermal growth factor receptor binding GO:0005154 9.16 CBL EGF
3 protein tyrosine kinase binding GO:1990782 8.62 CBL PTEN

Sources for Adrenal Cortical Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....